StreetInsider.com News Articles

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a

Rodman & Renshaw Starts vTv Therapeutics (VTVT) at Buy

Tue, 30 Jun 2026 07:56:52 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a price target of $67.00.

The analyst comments "We are initiating coverage of vTv Therapeutics with a BUY rating and $67 price target anchored to the commercial potential of cadisegliatin (TTP399), a first‑in‑class oral, liver‑selective glucokinase activator in development as an adjunct to insulin for Type 1 diabetes (T1D). Cadisegliatin holds FDA Breakthrough Therapy designation and Phase 2 data showing improved HbA1c, fewer hypoglycemic events, and no increase in diabetic ketoacidosis (DKA), supporting a differentiated clinical profile versus prior adjunctive T1D therapies.

Rodman & Renshaw Starts vTv Therapeutics (VTVT) at Buy

Tue, 30 Jun 2026 07:56:52 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a price target of $67.00.

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: 667, L.P.

Mon, 29 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707115.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: 667, L.P.

Mon, 29 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707115.html

Form 8-K vTv Therapeutics Inc. For: Jun 26

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706620.html

Form 8-K vTv Therapeutics Inc. For: Jun 26

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706620.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: AKKARAJU SRINIVAS

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706527.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: AKKARAJU SRINIVAS

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706527.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: SPIEGELMAN DANIEL K

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706532.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: SPIEGELMAN DANIEL K

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706532.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: Al-Marzooqi Fahed

Mon, 29 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260629/26706507.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: Al-Marzooqi Fahed

Mon, 29 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260629/26706507.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: Phillips Anne M.

Mon, 29 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260629/26706495.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: Phillips Anne M.

Mon, 29 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260629/26706495.html

Form DEFA14A vTv Therapeutics Inc.

Wed, 10 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26629979.html

Form DEFA14A vTv Therapeutics Inc.

Wed, 10 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26629979.html

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company’s

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company’s

vTv Therapeutics (VTVT) PT Lowered to $45 at H.C. Wainwright

Thu, 14 May 2026 06:44:38 -0400

(Updated - May 14, 2026 6:44 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on vTv Therapeutics (NASDAQ: VTVT) to $45.00 (from $47.00) while maintaining a Buy rating.

The analyst commented: "Yesterday after market close, vTv reported 1Q26 earnings and provided a corporate update, reiterating enrollment timelines. We remind, in March, the company updated its enrollment guidance for the CATT1 trial evaluating cadisegliatin (cadi) in Type 1 Diabetes (T1D) as an insulin adjuvant therapy, shifting from completion in 1H26 to 3Q26. The trial (NCT06334133) is now actively enrolling and dosing patients across 56 sites, which is in-line with management's

vTv Therapeutics (VTVT) PT Lowered to $45 at H.C. Wainwright

Thu, 14 May 2026 06:44:38 -0400

(Updated - May 14, 2026 6:44 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on vTv Therapeutics (NASDAQ: VTVT) to $45.00 (from $47.00) while maintaining a Buy rating.

Form 424B2 vTv Therapeutics Inc.

Wed, 13 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260513/26487618.html

Form 424B2 vTv Therapeutics Inc.

Wed, 13 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260513/26487618.html

Form 8-K vTv Therapeutics Inc. For: May 13

Wed, 13 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26487597.html